News

Under the purchase, OPKO intends to include Cytochroma’s Replidea and Alpharen, which are in Phase 3 clinical trials with kidney disease patients, into its product portfolio. Vitamin D

Transfer of all assets and liabilities of MorphoSys’ research and diagnostic antibody segment, the AbD Serotec, in addition to all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys

The project that is scheduled for three years and is being funded by IWT, will focus on advancing the development of the company’s candidate drug targeting DNA pol

The double-blind, placebo-controlled study was conducted in patients suffering from platinum-sensitive epithelial ovarian cancer in first relapse to evaluate farletuzumab (MORAb-003) combination therapy. Morphotek president and CEO Dr.

The results of vehicle-controlled, double-blind, randomised Phase 2b study support the advancement of Nexagon into Phase 3 registration trials. The UNC Limb Salvage/Wound Healing Center medical director and

The temporary arrangement is to address the present critical shortage of non-FDA approved Sodium Bicarbonate Injection, USP in the region. Sagent president, chief executive officer and board chairman

The COPD therapy, administered using the ELLIPTA inhaler, is a combination of GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2

Galapagos CEO Onno van de Stolpe said the company has identified five candidate drugs of which two have been in-licensed by GSK to date, since the start of

ARGAMATE Granule is indicated for the treatment of hyperkalemia resulting from acute or chronic renal failure and it helps in withdrawing the unnecessary potassium in the gastrointestinal tract.